Laobaixing Pharmacy Chain (LBX Pharmacy), a Chinese retail pharmacy chain backed by EQT Partners, closed up 44% on its price on the first day of trading in Shanghai.
Greater China | 24 Apr 2015 |
GIC Private, China Renaissance Capital Investment (CRCI) and GL Capital Group are among 26 investors subscribing to a HK$5 billion ($645 million) share placement by China Traditional Chinese Medicine (China TCM), intended to generate capital for acquisitions.
Expansion | 22 Apr 2015 |
Australian life sciences-focused VC firm Brandon Capital has reached a A$200 million ($154 million) final close on its latest vehicle - the Medical research Commercialisation Fund 3 (MTCF 3).
Australasia | 21 Apr 2015 |
Singapore state-backed investment group Temasek Holdings has invested INR9.45 billion ($151 million) in India's Glenmark Pharma via a preferential allotment of shares.
South Asia | 20 Apr 2015 |
Hony Capital has sold HK$9.78 billion ($1.26 billion) worth of shares in CSPC Pharmaceutical to complete its exit from the Hong Kong-listed Chinese drug manufacturer.
Exits | 17 Apr 2015 |
Alibaba Group plans to inject the operations of its online pharmacy business into Alibaba Health Information Technology (Alibaba Health), a Hong Kong-listed healthcare company that it bought alongside Yungfeng Capital last year, in a deal worth HK$19.4...
Greater China | 15 Apr 2015 |
TVM Capital Life Science has reached a first close of $50 million on its debut China fund, which will invest in Western companies with a view to obtaining licenses for development and commercialization in China.
Healthcare | 14 Apr 2015 |
Warburg Pincus has exited its entire 27% stake in Indian healthcare chain Metropolis to the Shah family, one of the company's promoters. KKR backed the Shah family's buyback.
Healthcare | 10 Apr 2015 |
Meinian Onehealth Healthcare Group, the largest private provider of preventive healthcare check-up services in China and a portfolio company of The Carlyle Group among others, plans to list in Shenzhen through a reverse merger with Jiangsu Sanyou Group.
Greater China | 30 Mar 2015 |
Healthcare-focused Vivo Capital has attracted increasing attention from LPs for its hybrid focus on the US and China. As testament to this, its latest fund - Vivo Capital Fund VIII - closed at $750 million after nine months in the market, with demand...
Greater China | 25 Mar 2015 |
Megakaryon, a Japan-based stem cell technology developer, has raised JPY2.54 billion ($21.2 million) from a consortium of investors including existing backers Innovation Network Corporation of Japan (INCJ), Mitsubishi UFJ Capital, SMBC Venture Capital...
North Asia | 25 Mar 2015 |
US-based Vivo Capital has closed its eighth fund at $750 million. It will invest in healthcare companies in the US and China.
Venture | 19 Mar 2015 |
Indonesia’s middle market is a proxy for the robust services sector, but it is difficult for investors to penetrate and deal flow has been slow in recent years. Are we are about to see more?
Southeast Asia | 18 Mar 2015 |
Updating your subscription status
In 2015, China is expected to experience a "new normal of growth". For private equity investors, China's new stage of growth represents huge opportunities: an increase of 270% in online consumption, the reform of over a hundred sovereign-owned enterprises, trillion-dollar investments into overseas infrastructure projects, the rising entrance of young entrepreneurs, and many more.
To be held on 28 and 29 May, the 14th annual AVCJ China Forum 2015 in Beijing will feature these exciting topics and bring together top-notch speakers from across the world.Join the premium industrial gathering of over 300 private equity professionals, regulators and senior executives for two days of mind-provoking discussions, networking and more.
28-29 May 2015, China World Summit Wing,Beijing
There is a feeling that now is a shrewd time to invest in Japan and take advantage of the favourable conditions for private equity. Valuations are low compared with the rest of Asia and strategic buyers and the IPO market are providing an attractive route for exits. There are also signs that corporate Japan is slowly coming around to engaging PE as a potential buyer for non-core assets and recent developments at the GPIF suggest that PE will be under strong consideration for allocations from pension funds in the near future as well as regional banks committing to the asset class right now.
The macro concerns that have been present for many years still remain in terms of low growth and currency depreciation but these are encouraging times for fund managers looking to both raise capital from Japanese LPs and make investments.
245-26 June 2015, Conrad Hotel, Tokyo